3553-12-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Acetylaminopyrazole is used as a building block for the synthesis of various drugs and biologically active compounds, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
3-Acetylaminopyrazole is used as a reagent in organic synthesis, facilitating the creation of complex organic molecules and compounds.
Used in Agrochemicals:
3-Acetylaminopyrazole is used as a versatile intermediate in the synthesis of agrochemicals, aiding in the development of effective and targeted pest control solutions.
Used in Medicinal Chemistry:
3-Acetylaminopyrazole is used as a reagent in the preparation of pyrazole-based Schiff bases, which have potential applications in the field of medicinal chemistry, including the development of new pharmaceutical agents.
Used in Antibacterial and Antifungal Applications:
3-Acetylaminopyrazole is used for its antibacterial and antifungal properties, offering potential solutions for treating infections caused by various microorganisms.

InChI:InChI=1/C5H7N3O/c1-4(9)7-5-2-3-6-8-5/h2-3H,1H3,(H2,6,7,8,9)

Upstream product

• 108-24-7 acetic anhydride 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 75-36-5 acetyl chloride 
• 90000-72-9 N-(2-acetyl-2H-pyrazol-3-yl)-acetamide 
• 1820-80-0 3-aminopyrazole 
• 72159-21-8 N-(1-benzyl-1H-pyrazol-3-yl)-acetamide 

Downstream Products

• 1251929-61-9 N-{1-[(2-fluorophenyl)methyl]-1H-pyrazol-3-yl}acetamide 
• 1251929-60-8 N-{1-[(2,6-difluorophenyl)methyl]-1H-pyrazol-3-yl}acetamide 
• 909861-89-8 N-{1-[(2-chloro-6-fluorophenyl)methyl]-1H-pyrazol-3-yl}acetamide 
• 1251929-58-4 C₁₂H₁₁ClFN₃O 
• 1606126-38-8 N-(4-(phenylethynyl)-1H-pyrazol-5-yl)acetamide 
• 141853-26-1 3-Acetamido-1-methyl-4-nitropyrazole 

Relevant academic research and scientific papers

TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

Pyrrolidinone derivative as glucokinase activator and preparation method and application thereof

The invention provides a pyrrolidone derivative, and more specifically relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. These compounds and contain their pharmaceutical compositions useful as glucokinase activators for the treatment of metabolic diseases and disorders. R1 . R2 , R3 , R4 , R5 , X And A are as described in the present invention.

Deuterated pyrrolidone derivative Pharmaceutical compositions and uses thereof

The invention relates to a deuterated pyrrolidone derivative and a preparation method thereof, and also relates to application of the deuterated pyrrolidone derivative and a pharmaceutical composition thereof in treatment and prevention of metabolic disorder related diseases, and belongs to the field of medicines.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

(PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS

A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: (I), Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, -CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof

Compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and at least one 5-membered aza heteroaromatic keratin dyeing compound with an N-hydroxy or N-amino group and derivatives thereof. A method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.